NENoura Atef A Ebrahim

Noura Atef A Ebrahim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noura Atef A Ebrahim has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neural Remodeling Across Cancer Evolution: Temporal, Spatial, Cellular, and Functional Principles of Tumor–Nerve Ecosystems

    by Noura A. A. Ebrahim, Rasha Aziz Attia Salama, Soliman M. A. Soliman

    Cancer neuroscience now asks not only whether tumors contain nerves, but how neural architecture, neuronal and glial states, and neural output change through cancer evolution. This critical narrative review integrates evidence from precursor lesions, primary tumors, invasion, metastasis, and treatment-associated states, while distinguishing neural remodeling from axonogenesis, neurogenesis, perineural invasion, and direct synaptic integration. We compare trophic, axon-guidance, metabolic, extracellular-vesicle, stromal, and neuroimmune mechanisms and emphasize that the direction of neural effects depends on stage, neuronal subtype, receptor context, and tissue immunity. The review operationalizes the proposed neural microdomain as a spatially bounded, measurable unit linking neural identity and topology to neighboring tumor, immune, stromal, and vascular states. It also separates neural abundance, neural state, and neural activity, and applies a consistent evidence taxonomy spanning anatomical, molecular, preclinical functional, human observational, and interventional evidence. Recent reports involving treatment-associated remodeling, systemic circuits, metastatic adaptation, and neural biomarkers are treated as emerging or preclinical where appropriate. We provide practical criteria for microdomain measurement, patient-level quantitative analysis, controls for denervation-related confounding, and distinctions among prognostic, predictive, and response biomarkers. The central translational conclusion is that neural interventions should be stage- and circuit-specific, biomarker-supported, and designed to preserve essential physiological neural functions.

  • Smart magnetic materials in 4D bioprinting: redefining neural tissue engineering

    by Doaa Abdelhameed, Noura A. A. Ebrahim, Hoda A. Ahmed, Ayman M. Mostafa, Ayman A. O. Younes, Soliman M. A. Soliman


  • Open Access

    Immunosenescence and cancer predisposition in pediatric transplant recipients: An emerging paradigm

    by Aya Mohamed Adel Arafat, Soliman M A Soliman, Habiba Elfandy, Moamen O Othman, Walaa Elsayed, Mai M Lotfy, Noura A A Ebrahim

    Pediatric solid organ and hematopoietic stem cell transplant recipients paradoxically experience accelerated immune aging despite chronological youth, establishing a paradigm with profound implications for cancer risk and long-term outcomes. This comprehensive review synthesizes current evidence demonstrating how transplantation-related factors, anti-thymocyte globulin-mediated T cell depletion, cytomegalovirus reactivation, chronic immunosuppression, and thymic dysfunction, induce premature immunosenescent phenotypes. These processes converge to generate T cell populations exhibiting CD28 loss, killer cell lectin-like receptor G1 positivity, telomere attrition, and functional exhaustion characteristic of elderly individuals. Concurrently, inflammaging pathways and senescence-associated secretory phenotypes establish pro-tumorigenic microenvironments. Consequently, pediatric recipients demonstrate 4- to 20-fold elevated cancer incidence, with standardized incidence ratios for post-transplant lymphoproliferative disease exceeding 200 in some cohorts. Beyond hematological malignancies, significant increases in solid tumors suggest fundamental immunosurveillance failure. Emerging biomarkers including flow cytometric senescence panels, telomere length measurement, and epigenetic clocks enable personalized risk stratification. Therapeutic horizons encompass senolytic agents, checkpoint inhibitor modulation, thymic regeneration strategies, and metabolic interventions targeting aging pathways. This paradigm shift necessitates reconceptualizing pediatric transplantation through the aging lens, integrating precision medicine approaches that balance graft survival, immune competence preservation, and cancer prevention in this vulnerable population.

  • Open Access

    Mapping HLA class I and II allele associations with hepatitis C related liver disease progression in an Egyptian cohort

    by Mai M. Lotfy, Noura A. A. Ebrahim, Mohamed El-Kassas, Ashraf Omar Abdel-Aziz, Dalia Abdelhamid Omran, Dalia Abdelfatah, Ahmed B. Barakat, Amira Salah El-Din Youssef, Auhood Nassar, Hany K. Soliman, et al.

    Host genetic factors, particularly human leukocyte antigen (HLA) polymorphisms, play a crucial role in determining the immunological outcome of Hepatitis C virus (HCV) infection. These genetic variations may influence susceptibility, disease progression, and the development of severe liver complications such as liver cirrhosis and hepatocellular carcinoma (HCC). Given the predominance of HCV genotype 4 in Egypt, this study was designed to investigate the association between specific HLA Class I and Class II alleles and clinical outcomes in an Egyptian cohort of patients with chronic HCV infection. A total of 223 participants were enrolled and stratified into four clinically defined categories: healthy controls (n = 55), patients with chronic hepatitis C (n = 86), liver cirrhotic patients (n = 42), and individuals with HCV-related HCC (n = 40). HLA genotyping was performed using the LABType® sequence-specific oligonucleotide (SSO) probe assay. Clinical and demographic data were collected between 2014 and 2016, before the implementation of Egypt's nationwide HCV eradication program, launched in 2018. This study identified differential HLA allele frequencies across HCV-related liver disease outcomes in an Egyptian cohort. HLA-DQB1*03, HLA-B*27, HLA-C*05, and HLA-A*26 showed high frequencies in healthy controls, whereas HLA-DRB1*14, HLA-A*69, HLA-B*52, HLA-B*58, and HLA-DRB1*15 appeared enriched in disease groups. Only HLA-DQB1*03 remained significant after Bonferroni correction. However, given the small sample size and lack of comprehensive national HLA data for direct comparison, these observations should be interpreted with caution. Alleles, such as HLA-B*44 and HLA-C*05, appeared absent in the HCC subgroup, though the significance of this finding remains uncertain due to low background frequencies in the control group. These preliminary data suggest possible associations of certain HLA alleles and HCV-related liver disease progression in Egyptian patients, possibly serving as candidate biomarkers for risk stratification. Nonetheless, larger, population-based studies with confirmed HCV genotyping, comprehensive treatment data, and updated controls reflecting current Egyptian HLA allele frequencies are needed to substantiate these associations.

  • Open Access

    Dynamic inflammation-based prognostication in acute-on-chronic liver failure: The COSSH-CAR model as a step forward in personalized risk stratification

    by Noura A A Ebrahim, Thoraya A Farghaly, Soliman M A Soliman

    Acute-on-chronic liver failure (ACLF) is a swiftly deteriorating condition characterized by profound systemic inflammation and failure of multiple organ systems, leading to high early mortality. There remains a critical need for more effective biomarkers to facilitate timely and accurate risk assessment. Recent findings by Zhu and Yan demonstrated that evaluating temporal changes in the C-reactive protein to albumin ratio (CAR), especially the 7-day variation, offers superior prediction of 28-day mortality compared with single baseline measurements. By integrating the 7-day variation of CAR with the model for end-stage liver disease sodium score and the grade of hepatic encephalopathy, the Chinese Group on Study of Severe Hepatitis B (COSSH)-CAR model was created, which surpassed traditional prognostic tools such as the Child-Pugh, model for end-stage liver disease, and COSSH-ACLF. This comment highlights the importance of using dynamic biomarker trajectories rather than static values for prognostic evaluation. CAR is biologically compelling because it captures both the inflammatory burden and the patient’s nutritional/physiological reserve. While the COSSH-CAR model is promising and based on routinely obtainable laboratory data, its widespread adoption will depend on validation in larger, diverse, and non-hepatitis B virus-related cohorts. Future work should examine CAR kinetics in prospective and interventional studies and consider how they may support individualized management strategies. Collectively, these observations suggest that the CAR could represent an important addition to current ACLF prognostic frameworks.


  • Open Access

    Synergistic mesenchymal and neural stem cell therapy: Advancing neurorestoration in cerebral infarction

    by Noura A A Ebrahim, Moamen O Othman, Neveen S Tahoun, Thoraya A Farghaly, Soliman M A Soliman

    Recent clinical and translational studies have increasingly highlighted the promise of combined stem cell strategies for neurorestoration following ischemic stroke. In this correspondence, we reflect on the recent trial by Yang et al , which reported that co-transplantation of mesenchymal stem cells (MSCs) and neural stem cells (NSCs) yielded significantly greater functional recovery in patients with acute cerebral infarction, as evidenced by improvements in both Barthel Index and National Institutes of Health Stroke Scale scores. Notably, this dual-cell intervention was accompanied by robust elevation of angiogenic and neurotrophic mediators, particularly vascular endothelial growth factor and basic fibroblast growth factor, suggesting a biologically plausible mechanism for the observed clinical benefit. MSCs contribute through trophic support, immunomodulatory effects, and promotion of vascular regeneration, whereas NSCs primarily facilitate neuronal replacement and reorganization of neural circuits. Together, these mechanisms offer a comprehensive, multitargeted approach to address the multifactorial nature of stroke pathology. Building on this pivotal work, we call for mechanistic studies and multicenter randomized clinical trials to refine cell dosing, timing, and bioengineering strategies, paving the way for the clinical integration of MSC/NSC co-therapy as a next-generation regenerative treatment for stroke.


  • Open Access

    Clinicopathological and prognostic insights into Embryonal Tumors with Multilayered Rosettes (ETMRs)

    by Noura A. A. Ebrahim, Heba A. Abdelbaky, Ahmed Mustafa Abd Elsalam, Mustafa A Hussein, Nancy H Amin

    Background: Embryonal tumors with multilayered rosettes (ETMRs) are rare, highly aggressive pediatric brain neoplasms characterized by early onset and dismal prognosis. This study presents a comprehensive clinicopathological and molecular analysis of ETMR cases diagnosed over a 14-year period at National Cancer Institute, Cairo University, with a focus on diagnostic features, clinical presentation, and survival outcomes. Methods: A retrospective review of 35 patients with histopathologically confirmed ETMRs was conducted. Demographic data, clinical symptoms, neuroimaging findings, histopathologic features-including rosette formation, mitotic activity, necrosis, and Ki67 proliferation index-as well as molecular analyses for C19MC amplification and LIN28A expression were evaluated. Kaplan-Meier survival curves and univariable Cox regression were used to assess prognostic associations. Results: The cohort comprised 17 females and 18 males, with a median age of 36 months. Common presenting symptoms included signs of raised intracranial pressure, seizures, and motor deficits. Gross total resection was achieved in 43% of patients, and 48% received adjuvant chemoradiotherapy.Histopathologic examination consistently revealed ependymoblastic rosettes (true multilayered rosettes) and high mitotic activity. LIN28A was diffusely expressed in all assessable cases. Molecular confirmation by PCR testing was done in 20 cases. The median overall survival was 19 months. Factors associated with inferior survival included incomplete surgical resection, absence of adjuvant therapy, and presence of necrosis and high mitotic index. Conclusion: ETMRs demonstrate consistent histological and immunohistochemical features that can guide diagnosis in resource-limited settings. Despite therapeutic advances, prognosis remains poor, underscoring the urgent need for novel therapeutic strategies. Molecular testing for C19MC amplification and LIN28A expression supports diagnostic confirmation and may hold future prognostic or therapeutic relevance.


  • Open Access

    Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms

    by Noura A A Ebrahim, Habiba Elfandy, Aya Mohamed Adel Arafat, Amira Diyaa Darwish, Mahitab Ibrahim Eltohamy

    BACKGROUND The E3 ubiquitin ligase murine double minute 2 (MDM2) is a key negative regulator of the tumor suppressor protein p53 and has been implicated in the development of various cancers, including hematologic malignancies. In multiple myeloma (MM), increased MDM2 expression has been reported and may play a role in disease progression and resistance to therapy. Despite this, the prognostic implications of MDM2 detected through immunohistochemistry (IHC) remain insufficiently defined. AIM To evaluate the clinical, pathological, and prognostic significance of MDM2 expression in plasma cell neoplasms, with a focus on its potential utility as an early indicator of disease severity and therapeutic response. METHODS A retrospective analysis was conducted on 71 patients diagnosed with MM or related plasma cell disorders treated at the National Cancer Institute between 2018 and 2022. MDM2 protein expression was assessed using IHC on extramedullary lesion biopsy samples, employing the MDM2 (A.M.1) monoclonal antibody. Nuclear staining in at least 1% of plasma cells was used as the threshold for MDM2 positivity. Comparative analyses were performed between MDM2-positive and MDM2-negative groups, examining clinical characteristics, laboratory data, histopathological features, treatment responses at 12 weeks and 24 weeks, and survival outcomes, including relapse-free survival (RFS) and overall survival. RESULTS MDM2 expression was identified in 30% of patient samples. While no major differences were observed in baseline demographics, disease stage, or most laboratory values, serum albumin levels were significantly lower in MDM2-positive patients (P = 0.007). At 12 weeks, patients with MDM2-positive disease showed significantly poorer treatment responses based on International Myeloma Working Group criteria (P = 0.002), and early clinical response was moderately negatively correlated with MDM2 expression (Spearman’s P = 0.375, P = 0.001). This correlation was not observed at 24 weeks. Immunophenotypic analysis indicated that MDM2-positive plasma cells exhibited lower epithelial membrane antigen (P = 0.014) and higher CD45 expression (P = 0.039), suggesting altered differentiation. Kaplan-Meier survival analysis demonstrated a markedly shorter median RFS in the MDM2-positive group (22 months vs 68 months, P < 0.001), although no significant difference was found in overall survival. CONCLUSION IHC-detected MDM2 overexpression identifies a distinct subset of plasma cell neoplasms characterized by reduced early treatment responsiveness and significantly shorter RFS. These findings support the potential of MDM2 as a prognostic biomarker for early relapse risk in MM. Incorporating MDM2 assessment into diagnostic and prognostic workflows may enable more individualized treatment approaches. Further validation through prospective studies is recommended.

  • Saliva-based molecular diagnostics in oral squamous cell carcinoma (OSCC): a non-invasive frontier in oncology

    by Noura A. A. Ebrahim, Soliman M. A. Soliman, Thoraya A. Farghaly

    Saliva is increasingly recognized as a powerful, noninvasive biofluid for the diagnosis and monitoring of oral squamous cell carcinoma (OSCC), serving as a practical alternative to conventional liquid biopsy. Salivary circulatory DNA (ctDNA) detection in OSCC may exceed plasma levels. emphasizing saliva's susceptibility to local illness. Saliva collection is simple, non-invasive, and inexpensive, allowing for regular monitoring. Current evidence demonstrates its potential through a wide spectrum of salivary biomarkers. Identified salivary biomarkers include viral nucleic acids such as human papillomavirus (HPV), host-derived molecules such as proteins and cytokines (IL-6, IL-8, VEGF), regulatory microRNAs (e.g., miR-21, miR-31, miR-184), and extracellular vesicles containing tumor-specific cargo. Moreover, oral microbiome dysbiosis has been linked to malignant transformation and progression, highlighting saliva's ability to reflect complex tumor-host interactions. Technological progress in multi-omics profiling and artificial intelligence (AI) has enhanced the interpretation of these multidimensional datasets, supporting the design of more robust and individualized biomarker panels. Concurrently, point-of-care technologies, particularly microfluidic chips and biosensor platforms, are driving the development of rapid and portable saliva-based diagnostics. CONCLUSION: The path toward clinical implementation is constrained by several factors: the absence of FDA-approved salivary assays for OSCC, reliance on relatively small and retrospective studies, and the lack of standardized protocols for collection, processing, and analysis. Despite these challenges, salivary diagnostics are advancing as a highly promising adjunct to established modalities such as histopathology and radiologic imaging. They hold potential in early disease detection, patient stratification, therapeutic monitoring, and surveillance of recurrence. Integrative models, such as liquid TNM staging-which combine salivary and blood-based biomarkers-may ultimately redefine cancer diagnostics and follow-up. To date, no saliva-based assay has received FDA approval for oral cancer, highlighting regulatory and validation shortcomings. For translation into practice, further validation through large-scale trials, regulatory endorsement, and demonstration of cost-effectiveness remain essential. Nonetheless, saliva-based assays stand out as accessible, patient-centered tools with significant implications for the future of head and neck oncology.